Literature DB >> 12100089

CNS effects of sumatriptan and rizatriptan in healthy female volunteers.

J van der Post1, M T Schram, R C Schoemaker, M S M Pieters, E Fuseau, A Pereira, S Baggen, A F Cohen, J M A van Gerven.   

Abstract

This study investigates the CNS effects of sumatriptan and rizatriptan, with temazepam as an active comparator, in healthy female volunteers. Sixteen volunteers completed a randomized, double-blind, crossover study and on four separate occasions received either 100 mg sumatriptan, 20 mg rizatriptan or 20 mg temazepam. The main parameters were eye movements, EEG, body sway, visual analogue scales and a cognitive test battery. Rizatriptan and sumatriptan decreased saccadic peak velocity by 18.3 (95% CI: 5.7, 30.8) and 15.0 (2.2, 27.9) degrees/sec, respectively, about half the decrease induced by temazepam (35.0 (22.1, 47.8) degrees/sec). Body sway increased (30% for rizatriptan (16%, 45%) and 14% for sumatriptan (1%, 27%), respectively). Temazepam caused larger, similar effects. In contrast to temazepam, sumatriptan and rizatriptan decreased reaction times of recognition tasks and increased EEG alpha power (significant for sumatriptan, 0.477 (0.02, 0.935). Therapeutic doses of sumatriptan and rizatriptan caused CNS effects indicative of mild sedation. For EEG and recognition reaction times the effects were opposite to temazepam, indicating central stimulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100089     DOI: 10.1046/j.1468-2982.2002.00344.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  Dizziness produced by a potent 5HT(1A) receptor agonist (eptapirone) is not due to postural hypotension.

Authors:  S J Wilson; J E Bailey; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 2.  Where do triptans act in the treatment of migraine?

Authors:  Andrew H Ahn; Allan I Basbaum
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

Review 3.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

4.  Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Authors:  Marieke Liem-Moolenaar; Mandana Rad; Stefano Zamuner; Adam F Cohen; Francesca Lemme; Kari L Franson; Joop M A van Gerven; Emilio Merlo Pich
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 5.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

6.  Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Authors:  L Becerra; J Bishop; G Barmettler; Y Xie; E Navratilova; F Porreca; D Borsook
Journal:  J Neurophysiol       Date:  2015-10-21       Impact factor: 2.714

7.  Headaches related to triptans therapy in patients of migrainous vertigo.

Authors:  Sanjay Prakash; Bhavana V Chavda; Hiren Mandalia; Rishi Dhawan; Deepak Padmanabhan
Journal:  J Headache Pain       Date:  2008-04-22       Impact factor: 7.277

8.  A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.

Authors:  Joseph M Furman; Dawn A Marcus
Journal:  Int J Med Sci       Date:  2009-08-06       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.